Cancer Drug Co. Athenex Raises $66M After IPO Prices Low
Cancer-focused biotechnology company Athenex Inc. raised $66 million through an initial public offering that priced at the bottom of its range Wednesday, the first of four scheduled IPOs this week during...To view the full article, register now.
Already a subscriber? Click here to view full article